John Libbey Eurotext

Hématologie

MENU

Mantle cells lymphoma: standards and news Volume 21, issue 3, Mai-Juin 2015

Figures

  • Figure 1

Tables

Authors
1 Service d’hématologie clinique, Institut de cancéro-hématologie CHRU Brest ; France
2 Service d’hématologie clinique du CHU de Nantes, UMR892 Inserm équipe 10, Nantes ; France
* Tirés à part

Mantle cell lymphoma (MCL) is a rare and agressive form of non Hodgkin's lymphoma with one of the worst outcomes. The last decades have established a standard treatment based on the use of cytarabine combined with rituximab followed by a therapeutic intensification and autologous transplantation in young patients. Despite this, LCM remains an aggressive entity with many relapses. Currently, a new era is emerging with the development of new targeted therapies that are coming to change our attitudes and therefore the prognosis of this disease. This review presents the current standard treatment and therapeutic developments in MCL.